What preventive treatment is recommended for a 46-year-old woman with chronic migraines occurring twice weekly who has not responded to triptans (e.g., consider galcanezumab [Emgality])?

Recommended Treatment for Chronic Migraine with Triptan Failure

For this 46-year-old woman with chronic migraines (twice weekly) who has failed triptans, initiate preventive therapy with a CGRP monoclonal antibody such as galcanezumab (Emgality), which is FDA-approved and specifically indicated for migraine prevention. 1

Why Preventive Therapy is Critical Here

This patient requires preventive treatment, not just acute therapy optimization. With 8+ migraine days per month (twice weekly), she meets criteria for chronic migraine and has already failed acute treatment with triptans. The 2025 American College of Physicians guidelines explicitly state: "If the episodic migraine occurs frequently or treatment does not provide an adequate response, the addition of preventive medications may be warranted." 2

Important caveat: This patient is at high risk for medication overuse headache given her frequent migraine pattern. Triptans used ≥10 days per month can cause medication overuse headache, which perpetuates the chronic migraine cycle. 2

First-Line Preventive Treatment Algorithm

Step 1: CGRP Monoclonal Antibodies (Preferred)

Galcanezumab (Emgality) is the optimal choice for several reasons:

• FDA-approved specifically for migraine prevention with a loading dose of 240 mg subcutaneously, followed by 120 mg monthly 1
• Proven efficacy in patients who failed prior preventives: In the CONQUER trial, galcanezumab reduced monthly migraine headache days by 4.1 days versus 1.0 days for placebo in patients with 2-4 prior preventive failures 3
• Superior to traditional oral preventives: The TRIUMPH study showed 48.3% of galcanezumab patients achieved ≥50% reduction in migraine days versus 35.9% with traditional oral preventives (topiramate, amitriptyline, etc.) 4
• Rapid onset: Greatest improvement occurs in the first 3 months 5
• Converts chronic to episodic migraine: 65.1% of patients shifted from chronic to episodic migraine frequency over 12 months 6

Step 2: Alternative CGRP-Targeted Therapies

If galcanezumab is not accessible due to insurance or cost barriers, consider:

• Fremanezumab (quarterly or monthly dosing)
• Erenumab (monthly dosing)
• Eptinezumab (quarterly IV infusion)
• Atogepant (oral daily CGRP antagonist-gepant)

All show similar efficacy profiles, with network meta-analysis suggesting fremanezumab and eptinezumab may have slightly higher effect sizes 7

Step 3: Traditional Oral Preventives (If CGRP Therapies Unavailable)

Per 2025 ACP guidelines, if CGRP therapies are not accessible, initiate: 8

First-line options:

• Beta-blockers: metoprolol or propranolol
• Antiseizure: topiramate or valproate (contraindicated in women of childbearing potential)
• Antidepressants: amitriptyline (TCA) or venlafaxine (SNRI)

However, the evidence strongly favors CGRP therapies over these traditional agents in patients with prior treatment failures 4, 7

Acute Treatment Optimization During Preventive Therapy

While initiating preventive therapy, optimize acute treatment:

1. If triptans failed as monotherapy: Add NSAID to triptan (e.g., sumatriptan 100 mg + naproxen 500 mg) 2
2. If combination triptan + NSAID fails: Consider CGRP antagonist-gepants (rimegepant, ubrogepant, zavegepant) for acute treatment 2
3. Avoid opioids and butalbital - these worsen medication overuse headache 2

Critical Monitoring Points

• Medication overuse assessment: Document current acute medication use frequency. If using triptans ≥10 days/month, counsel on medication overuse headache risk 2
• Response evaluation window: Assess preventive efficacy at 3 months minimum, though some patients respond within weeks 5, 9
• Treatment adherence: Monthly subcutaneous injections have high adherence rates (81% completion at 12 months) 9
• Blood pressure monitoring: CGRP antagonists can cause hypertension; monitor BP, especially if pre-existing risk factors 1

Special Considerations for This Patient

Age 46 (reproductive age): If pregnancy is possible, discuss teratogenic risks:

• Valproate is strictly contraindicated in women of childbearing potential 10
• CGRP therapies have limited pregnancy data; discuss risks/benefits 1
• Topiramate has teratogenic potential

Quality of life impact: Galcanezumab significantly improves MSQ Role Function-Restrictive scores, addressing the disability burden of chronic migraine 1, 3

Expected Outcomes with Galcanezumab

Based on clinical trial data 1, 6, 9:

• Mean reduction: 4.3-4.7 monthly migraine headache days
• ≥50% response rate: 59-62% of patients
• ≥75% response rate: 34-39% of patients
• Conversion to episodic migraine: 65% over 12 months
• Adverse events: Generally mild (injection site reactions most common); discontinuation rate due to adverse events only 5%